Thus, integrating pharmacogenetic testing for CYP enzymes into MDD clinical management could allow healthcare providers to establish a personalized antidepressant treatment, which would minimize the risk of adverse drug reactions and improve the effectiveness of pharmacotherapy for depression (112–114). This evidence concerns the gene PPIG and major depressive disorder.